MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

20.33 0.54

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.81

Максимум

20.64

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+71.93% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-194M 2B
Предишно отваряне	19.79
Предишно затваряне	20.33

Настроения в новините

By Acuity

50%

166 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2026 г., 17:11 ч. UTC

Значими двигатели на пазара

Значими събития в новините

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2.04.2026 г., 17:10 ч. UTC

Значими събития в новините

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3.04.2026 г., 00:00 ч. UTC

Значими събития в новините

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2.04.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2.04.2026 г., 21:01 ч. UTC

Значими събития в новините

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2.04.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Starbucks and Boyu Capital Finalize China JV

2.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.04.2026 г., 20:41 ч. UTC

Печалби

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2.04.2026 г., 20:32 ч. UTC

Пазарно говорене

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2.04.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2.04.2026 г., 20:09 ч. UTC

Пазарно говорене

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2.04.2026 г., 20:01 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2.04.2026 г., 19:46 ч. UTC

Пазарно говорене

Is Oil the New GameStop? -- Market Talk

2.04.2026 г., 19:35 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2.04.2026 г., 19:29 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2.04.2026 г., 19:24 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2.04.2026 г., 19:20 ч. UTC

Пазарно говорене

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2.04.2026 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2.04.2026 г., 19:00 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific: Agreement Reached With American Train Dispatchers Association

2.04.2026 г., 18:24 ч. UTC

Придобивния, сливания и поглъщания

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2.04.2026 г., 17:44 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2.04.2026 г., 17:32 ч. UTC

Значими събития в новините

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2.04.2026 г., 17:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2.04.2026 г., 17:17 ч. UTC

Пазарно говорене

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2.04.2026 г., 17:09 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

71.93% нагоре

12-месечна прогноза

Среден 34.97 USD 71.93%

Висок 47 USD

Нисък 21.8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

166 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.